Anastrozole vs Enclomiphene

Mechanism

Anastrozole is a potent, selective, non-steroidal third-generation aromatase inhibitor that competitively binds the heme group of cytochrome P450 aromatase (CYP19A1), blocking the conversion of testosterone to estradiol and androstenedione to estrone. In men on TRT, this reduces circulating estradiol by 50-80%, shifting the testosterone-to-estradiol ratio favorably. Estrogen suppression releases hypothalamic negative feedback, increasing GnRH, LH, and FSH secretion in non-TRT contexts. Complete estrogen ablation is detrimental to bone density, lipid metabolism, and cognitive function.

Standard Dosing

Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly.

Timing

Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control.

Cycle Duration

Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose.

Side Effects

• Joint pain and stiffness (from excessive estrogen suppression)
• Bone density loss with chronic use
• Lipid profile worsening (HDL suppression)
• Fatigue and brain fog (from over-suppression of estradiol)
• Mood disturbances and depression
• Hot flashes
• Decreased libido (if estradiol drops below ~15 pg/mL)

Contraindications

• Premenopausal women
• Known hypersensitivity to anastrozole
• Pre-existing severe osteoporosis (estrogen suppression worsens bone loss)
• Children (may affect bone growth plate closure)

Best Stacking Partners

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners